This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Ambrose, P. G.
Right arrow Articles by Pierce, P. F.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ambrose, P. G.
Right arrow Articles by Pierce, P. F.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, October 2001, p. 2793-2797, Vol. 45, No. 10
0066-4804/01/$04.00+0   DOI: 10.1128/AAC.45.10.2793-2797.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.

Pharmacodynamics of Fluoroquinolones against Streptococcus pneumoniae in Patients with Community-Acquired Respiratory Tract Infections

Paul G. Ambrose,1,* Dennis M. Grasela,2 Thaddeus H. Grasela,1 Julie Passarell,1 Howard B. Mayer,3 and Phillip F. Pierce3

Cognigen Corporation, Buffalo, New York1; Bristol-Myers Squibb Company, Princeton, New Jersey2; and Bristol-Myers Squibb Company, Wallingford, Connecticut3

Received 18 December 2000/Returned for modification 5 June 2001/Accepted 21 July 2001

Fluoroquinolone antibiotic agents have demonstrated efficacy in the treatment of respiratory tract infections. This analysis was designed to examine the relationship between drug exposure, as measured by the free-drug area under the concentration-time curve at 24 h (AUC24)/MIC ratio, and clinical and microbiological responses in patients with community-acquired respiratory tract infections involving Streptococcus pneumoniae. The study population included 58 adult patients (34 males, 24 females) who were enrolled in either of two phase III, randomized, multicenter, double-blind studies of levofloxacin versus gatifloxacin for the treatment of community-acquired pneumonia or acute exacerbation of chronic bronchitis. Clearance equations from previously published population pharmacokinetic models were used in conjunction with dose and adjusted for protein binding to estimate individual patient free-drug AUC24s. In vitro susceptibility was determined in a central laboratory by broth microdilution in accordance with NCCLS guidelines. Pharmacodynamic analyses were performed on data from all evaluable patients with documented S. pneumoniae infection using univariate and multivariable logistic regression; pharmacodynamic breakpoints were estimated using Classification and Regression Tree analysis. A statistically significant (P = 0.013) relationship between microbiological response and the free-drug AUC24/MIC ratio was detected. At a free-drug AUC24/MIC ratio of <33.7, the probability of a microbiological response was 64%, and at a free-drug AUC24/MIC ratio of >33.7, it was 100% (P < 0.01). These findings may provide a minimum target free-drug AUC24/MIC ratio for the treatment of infections involving S. pneumoniae with fluoroquinolone antibiotics and provide a paradigm for the selection of fluoroquinolones to be brought forward from drug discovery into clinical development and dose selection for clinical trials. Further, when target free-drug AUC24/MIC ratios are used in conjunction with stochastic modeling techniques, these findings may be used to support susceptibility breakpoints for fluoroquinolone antibiotics and S. pneumoniae.

* Corresponding author. Mailing address: Infectious Diseases, Cognigen Corporation, 395 Youngs Rd., Buffalo, NY 14221-5831. Phone: (716) 633-3463, ext. 302. Fax: (716) 633-7404. E-mail: paul.ambrose{at}cognigencorp.com.

Antimicrobial Agents and Chemotherapy, October 2001, p. 2793-2797, Vol. 45, No. 10
0066-4804/01/$04.00+0   DOI: 10.1128/AAC.45.10.2793-2797.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.


This article has been cited by other articles:

  • Owens, R. C. Jr., Shorr, A. F. (2009). Rational dosing of antimicrobial agents: Pharmacokinetic and pharmacodynamic strategies. Am J Health Syst Pharm 66: S23-S30 [Abstract] [Full Text]  
  • Dooley, K., Flexner, C., Hackman, J., Peloquin, C. A., Nuermberger, E., Chaisson, R. E., Dorman, S. E. (2008). Repeated Administration of High-Dose Intermittent Rifapentine Reduces Rifapentine and Moxifloxacin Plasma Concentrations. Antimicrob. Agents Chemother. 52: 4037-4042 [Abstract] [Full Text]  
  • MacGowan, A. P., on behalf of the BSAC Working Parties on Resistanc, (2008). Clinical implications of antimicrobial resistance for therapy. J Antimicrob Chemother 62: ii105-ii114 [Abstract] [Full Text]  
  • Frei, C. R., Wiederhold, N. P., Burgess, D. S. (2008). Antimicrobial breakpoints for Gram-negative aerobic bacteria based on pharmacokinetic-pharmacodynamic models with Monte Carlo simulation. J Antimicrob Chemother 61: 621-628 [Abstract] [Full Text]  
  • Ambrose, P. G., Forrest, A., Craig, W. A., Rubino, C. M., Bhavnani, S. M., Drusano, G. L., Heine, H. S. (2007). Pharmacokinetics-Pharmacodynamics of Gatifloxacin in a Lethal Murine Bacillus anthracis Inhalation Infection Model. Antimicrob. Agents Chemother. 51: 4351-4355 [Abstract] [Full Text]  
  • Homma, T., Hori, T., Sugimori, G., Yamano, Y. (2007). Pharmacodynamic Assessment Based on Mutant Prevention Concentrations of Fluoroquinolones To Prevent the Emergence of Resistant Mutants of Streptococcus pneumoniae. Antimicrob. Agents Chemother. 51: 3810-3815 [Abstract] [Full Text]  
  • Turnidge, J., Paterson, D. L. (2007). Setting and Revising Antibacterial Susceptibility Breakpoints. Clin. Microbiol. Rev. 20: 391-408 [Abstract] [Full Text]  
  • Meagher, A. K., Passarell, J. A., Cirincione, B. B., Van Wart, S. A., Liolios, K., Babinchak, T., Ellis-Grosse, E. J., Ambrose, P. G. (2007). Exposure-Response Analyses of Tigecycline Efficacy in Patients with Complicated Skin and Skin-Structure Infections. Antimicrob. Agents Chemother. 51: 1939-1945 [Abstract] [Full Text]  
  • Li, C., Du, X., Kuti, J. L., Nicolau, D. P. (2007). Clinical Pharmacodynamics of Meropenem in Patients with Lower Respiratory Tract Infections. Antimicrob. Agents Chemother. 51: 1725-1730 [Abstract] [Full Text]  
  • Rubino, C. M., Capparelli, E. V., Bradley, J. S., Blumer, J. L., Kearns, G. L., Reed, M., Jacobs, R. F., Cirincione, B., Grasela, D. M. (2007). Population Pharmacokinetic Model for Gatifloxacin in Pediatric Patients. Antimicrob. Agents Chemother. 51: 1246-1252 [Abstract] [Full Text]  
  • LaPlante, K. L., Rybak, M. J., Tsuji, B., Lodise, T. P., Kaatz, G. W. (2007). Fluoroquinolone Resistance in Streptococcus pneumoniae: Area Under the Concentration-Time Curve/MIC Ratio and Resistance Development with Gatifloxacin, Gemifloxacin, Levofloxacin, and Moxifloxacin. Antimicrob. Agents Chemother. 51: 1315-1320 [Abstract] [Full Text]  
  • Koenig, S. M., Truwit, J. D. (2006). Ventilator-Associated Pneumonia: Diagnosis, Treatment, and Prevention. Clin. Microbiol. Rev. 19: 637-657 [Abstract] [Full Text]  
  • Burkhardt, O., Lehmann, C., Madabushi, R., Kumar, V., Derendorf, H., Welte, T. (2006). Once-daily tobramycin in cystic fibrosis: better for clinical outcome than thrice-daily tobramycin but more resistance development?. J Antimicrob Chemother 58: 822-829 [Abstract] [Full Text]  
  • Bakker-Woudenberg, I. A. J. M., ten Kate, M. T., Goessens, W. H. F., Mouton, J. W. (2006). Effect of Treatment Duration on Pharmacokinetic/Pharmacodynamic Indices Correlating with Therapeutic Efficacy of Ceftazidime in Experimental Klebsiella pneumoniae Lung Infection.. Antimicrob. Agents Chemother. 50: 2919-2925 [Abstract] [Full Text]  
  • DeRyke, C. A., Du, X., Nicolau, D. P. (2006). Evaluation of bacterial kill when modelling the bronchopulmonary pharmacokinetic profile of moxifloxacin and levofloxacin against parC-containing isolates of Streptococcus pneumoniae. J Antimicrob Chemother 58: 601-609 [Abstract] [Full Text]  
  • Griffith, D. C., Corcoran, E., Lofland, D., Lee, A., Cho, D., Lomovskaya, O., Dudley, M. N. (2006). Pharmacodynamics of Levofloxacin against Pseudomonas aeruginosa with Reduced Susceptibility Due to Different Efflux Pumps: Do Elevated MICs Always Predict Reduced In Vivo Efficacy?. Antimicrob. Agents Chemother. 50: 1628-1632 [Abstract] [Full Text]  
  • Smith, J., Safdar, N., Knasinski, V., Simmons, W., Bhavnani, S. M., Ambrose, P. G., Andes, D. (2006). Voriconazole therapeutic drug monitoring.. Antimicrob. Agents Chemother. 50: 1570-1572 [Abstract] [Full Text]  
  • Bhavnani, S. M., Passarell, J. A., Owen, J. S., Loutit, J. S., Porter, S. B., Ambrose, P. G. (2006). Pharmacokinetic-Pharmacodynamic Relationships Describing the Efficacy of Oritavancin in Patients with Staphylococcus aureus Bacteremia. Antimicrob. Agents Chemother. 50: 994-1000 [Abstract] [Full Text]  
  • Zelenitsky, S., Ariano, R., Harding, G., Forrest, A. (2005). Evaluating Ciprofloxacin Dosing for Pseudomonas aeruginosa Infection by Using Clinical Outcome-Based Monte Carlo Simulations. Antimicrob. Agents Chemother. 49: 4009-4014 [Abstract] [Full Text]  
  • Cazzola, M., Matera, M. G., Donnarumma, G., Tufano, M. A., Sanduzzi, A., Marchetti, F., Blasi, F. (2005). Pharmacodynamics of Levofloxacin in Patients With Acute Exacerbation of Chronic Bronchitis. Chest 128: 2093-2098 [Abstract] [Full Text]  
  • Booker, B. M., Smith, P. F., Forrest, A., Bullock, J., Kelchlin, P., Bhavnani, S. M., Jones, R. N., Ambrose, P. G. (2005). Application of an In Vitro Infection Model and Simulation for Reevaluation of Fluoroquinolone Breakpoints for Salmonella enterica Serotype Typhi. Antimicrob. Agents Chemother. 49: 1775-1781 [Abstract] [Full Text]  
  • Azoulay-Dupuis, E., Bedos, J. P., Mohler, J., Moine, P., Cherbuliez, C., Peytavin, G., Fantin, B., Kohler, T. (2005). Activity of Gemifloxacin against Quinolone-Resistant Streptococcus pneumoniae Strains In Vitro and in a Mouse Pneumonia Model. Antimicrob. Agents Chemother. 49: 1046-1054 [Abstract] [Full Text]  
  • Capparelli, E. V., Reed, M. D., Bradley, J. S., Kearns, G. L., Jacobs, R. F., Damle, B. D., Blumer, J. L., Grasela, D. M. (2005). Pharmacokinetics of Gatifloxacin in Infants and Children. Antimicrob. Agents Chemother. 49: 1106-1112 [Abstract] [Full Text]  
  • Van Wart, S., Phillips, L., Ludwig, E. A., Russo, R., Gajjar, D. A., Bello, A., Ambrose, P. G., Costanzo, C., Grasela, T. H., Echols, R., Grasela, D. M. (2004). Population Pharmacokinetics and Pharmacodynamics of Garenoxacin in Patients with Community-Acquired Respiratory Tract Infections. Antimicrob. Agents Chemother. 48: 4766-4777 [Abstract] [Full Text]  
  • Croisier, D., Etienne, M., Piroth, L., Bergoin, E., Lequeu, C., Portier, H., Chavanet, P. (2004). In vivo pharmacodynamic efficacy of gatifloxacin against Streptococcus pneumoniae in an experimental model of pneumonia: impact of the low levels of fluoroquinolone resistance on the enrichment of resistant mutants. J Antimicrob Chemother 54: 640-647 [Abstract] [Full Text]  
  • Croisier, D., Etienne, M., Bergoin, E., Charles, P.-E., Lequeu, C., Piroth, L., Portier, H., Chavanet, P. (2004). Mutant Selection Window in Levofloxacin and Moxifloxacin Treatments of Experimental Pneumococcal Pneumonia in a Rabbit Model of Human Therapy. Antimicrob. Agents Chemother. 48: 1699-1707 [Abstract] [Full Text]  
  • Florea, N. R., Tessier, P. R., Zhang, C., Nightingale, C. H., Nicolau, D. P. (2004). Pharmacodynamics of Moxifloxacin and Levofloxacin at Simulated Epithelial Lining Fluid Drug Concentrations against Streptococcus pneumoniae. Antimicrob. Agents Chemother. 48: 1215-1221 [Abstract] [Full Text]  
  • Capitano, B., Mattoes, H. M., Shore, E., O'Brien, A., Braman, S., Sutherland, C., Nicolau, D. P. (2004). Steady-State Intrapulmonary Concentrations of Moxifloxacin, Levofloxacin, and Azithromycin in Older Adults. Chest 125: 965-973 [Abstract] [Full Text]  
  • Morrissey, I., Tillotson, G. (2004). Activity of gemifloxacin against Streptococcus pneumoniae and Haemophilus influenzae. J Antimicrob Chemother 53: 144-148 [Abstract] [Full Text]  
  • Schentag, J. J, Meagher, A. K, Forrest, A. (2003). Fluoroquinolone AUIC Break Points and the Link to Bacterial Killing Rates Part 2: Human Trials. The Annals of Pharmacotherapy 37: 1478-1488 [Abstract] [Full Text]  
  • Amsden, G. W, Owens, R. C Jr, Bertino, J. S Jr (2003). AUIC in Humans: A Fact-Based Discussion. The Annals of Pharmacotherapy 37: 1518-1521 [Full Text]  
  • Scaglione, F., Mouton, J. W., Mattina, R., Fraschini, F. (2003). Pharmacodynamics of Levofloxacin and Ciprofloxacin in a Murine Pneumonia Model: Peak Concentration/MIC versus Area under the Curve/MIC Ratios. Antimicrob. Agents Chemother. 47: 2749-2755 [Abstract] [Full Text]  
  • Ambrose, P. G., Bhavnani, S. M., Cirincione, B. B., Piedmonte, M., Grasela, T. H. (2003). Gatifloxacin and the elderly: pharmacokinetic-pharmacodynamic rationale for a potential age-related dose reduction. J Antimicrob Chemother 52: 435-440 [Abstract] [Full Text]  
  • Nicolau, D. P., Mattoes, H. M., Banevicius, M., Xuan, D., Nightingale, C. H. (2003). Pharmacodynamics of a Novel Des-F(6)-Quinolone, BMS-284756, against Streptococcuspneumoniae in the Thigh Infection Model. Antimicrob. Agents Chemother. 47: 1630-1635 [Abstract] [Full Text]  
  • Zelenitsky, S. A., Ariano, R. E., Iacovides, H., Sun, S., Harding, G. K. M. (2003). AUC0-t/MIC is a continuous index of fluoroquinolone exposure and predictive of antibacterial response for Streptococcus pneumoniae in an in vitro infection model. J Antimicrob Chemother 51: 905-911 [Abstract] [Full Text]  
  • Jones, R. N., Rubino, C. M., Bhavnani, S. M., Ambrose, P. G. (2003). Worldwide Antimicrobial Susceptibility Patterns and Pharmacodynamic Comparisons of Gatifloxacin and Levofloxacin against Streptococcus pneumoniae: Report from the Antimicrobial Resistance Rate Epidemiology Study Team. Antimicrob. Agents Chemother. 47: 292-296 [Abstract] [Full Text]  
  • Lister, P. D. (2003). Impact of AUC/MIC ratios on the pharmacodynamics of the des-F(6) quinolone garenoxacin (BMS-284756) is similar to other fluoroquinolones. J Antimicrob Chemother 51: 199-202 [Full Text]  
  • Croisier, D., Chavanet, P., Lequeu, C., Ahanou, A., Nierlich, A., Neuwirth, C., Piroth, L., Duong, M., Buisson, M., Portier, H. (2002). Efficacy and pharmacodynamics of simulated human-like treatment with levofloxacin on experimental pneumonia induced with penicillin-resistant pneumococci with various susceptibilities to fluoroquinolones. J Antimicrob Chemother 50: 349-360 [Abstract] [Full Text]  
  • Ambrose, P. G., Owens, R. C. Jr, Garvey, M. J., Jones, R. N. (2002). Pharmacodynamic considerations in the treatment of moderate to severe pseudomonal infections with cefepime. J Antimicrob Chemother 49: 445-453 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»